tp53-mutant aml linked to poorer outcomes with decitabine plus venetoclax
Published 3 years ago • 292 plays • Length 1:48Download video MP4
Download video MP3
Similar videos
-
2:36
outcomes of tp53-mutant aml with venetoclax and decitabine
-
0:44
predictors of poor response to azacitidine, venetoclax, and magrolimab in tp53-mutated aml
-
1:36
eprenetapopt plus venetoclax and azacitidine in the treatment of tp53-mutated aml
-
2:26
impact of allelic state on os in tp53-mutant aml and hr-mds
-
1:26
updates in the treatment landscape of p53-mutated aml/mds
-
1:36
the synergetic mechanism of pivekimab sunirine and venetoclax and its potential for treating aml
-
1:38
the importance of targeting tp53 in aml and agents being explored
-
1:17
decitabine, venetoclax and ponatinib in patients with advanced cml and ph aml
-
0:44
unmet needs in aml: tp53 mutations and maintenance therapy
-
1:57
tolerability and efficacy of magrolimab plus azacitidine in tp53-mutated aml patients
-
5:16
an analysis of tp53 mutation in aml and hr-mds
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
2:23
improving treatment for patients with tp53-mutated myeloid malignancies
-
0:58
options available to patients with tp53-mutated mds beyond stem cell transplantation
-
4:15
phase ib/ii trial of quizartinib, decitabine and venetoclax in flt3-itd-mutated aml
-
0:41
promising agents in aml: menin inhibitors & magrolimab in tp53-mutated aml
-
3:00
apr-246 in tp53 mutated mds and aml
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:40
new therapeutic approaches targeting xpo1-overexpression in tp53-mutated myeloid malignancies